A proper clinical evaluation of patients with Multiple Sclerosis (MS) is of great importance to
detect MS progression. It provides important data for physicians on their daily practice as …

The identification of progression in multiple sclerosis is typically retrospective. Given the
profound burden of progressive multiple sclerosis, and the recent development of effective …

Background The safety and efficacy of ocrelizumab in primary progressive multiple sclerosis
were shown in the phase 3 ORATORIO trial. In this study, we assessed the effects of …

Background High-efficacy therapies in multiple sclerosis are traditionally used after
unsuccessful treatment with first-line disease modifying therapies. We hypothesised that …

The Canadian Multiple Sclerosis Working Group has updated its treatment optimization
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …

Abstract Background Evoked potentials (EPs) are a measure of the conductivity of the
central nervous system. They are used to monitor disease progression of multiple sclerosis …

Background Volume loss in the deep gray matter (DGM) has been reported in patients with
multiple sclerosis (MS) already at early stages of the disease and is thought to progress …

In multiple sclerosis, treatment start or switch is prompted by evidence of disease activity.
Whilst immunomodulatory therapies reduce disease activity, the time required to attain …

Importance It is unclear whether relapses and disease-modifying therapies are associated
with the rate of disability accumulation in patients with secondary progressive multiple …

The conversion of relapsing-remitting multiple sclerosis (RRMS) to secondary progressive
MS (SPMS) cannot be defined by a sharp threshold determined by event-based measures …